Bioresorbable Vascular Scaffold Market Size, Share, Trends, Growth, and Forecasts for 2025 - 2032

Bioresorbable Vascular Scaffold Market Size and Share Analysis

The global bioresorbable vascular scaffold market size is estimated to be valued at US$ 592.8 Million by 2032 from US$ 314.4 Million in 2025. It is expected to register a CAGR of 8.3% in the forecast period between 2025 and 2032.

Bioresorbable vascular scaffolds (BVS) have emerged as an innovative solution to traditional stents used in treating coronary artery disease (CAD). The BVS technology provides temporary support to the artery and then dissolves, allowing the vessel to regain its natural function. Next-generation bioresorbable scaffolds are being designed to better withstand vascular complications and adapt to individual patient anatomies. Further advancements in the field of interventional cardiology, driven by a paradigm shift toward personalized medicine, improved equipment manufacturing, and faster regulatory approvals, will fuel the bioresorbable vascular scaffold market growth in the forthcoming years.

Key Industry Highlights

• Increasing incidence of cardiovascular disease (CVD), growing demand for minimally invasive coronary artery disease treatment options, and advancements in interventional cardiology are the leading factors supporting the expansion of the bioresorbable scaffolds market.
• The development of biodegradable polymers and next-gen scaffold designs has been a key market trend.
• A notable advancement has been the engineering of novel polymers with improved biocompatibility profiles and controlled degradation rates.
• With an objective to enhance performance metrics, such as flexibility and radial strength, there has been a growing focus on innovating the structure of the scaffolds, which is benefiting the bioresorbable vascular scaffold market.

Market Dynamics

Driver - Growing prevalence of CVD and CAD to boost market growth

According to a 2023 report released by the World Heart Federation (WHF), CVD killed over 20 million people worldwide in 2021, emerging as the leading cause of death globally. Moreover, the American Heart Association revealed in a 2024 report that around 5% of Americans aged under 20 suffer from CAD. Patients afflicted by CVD or CAD often seek low-risk treatments with faster recovery times. Minimally invasive procedures (MIS) fulfil this preference among heart patients, with bioresorbable vascular scaffolds providing an efficient alternative to traditional surgical techniques. The alignment between changing patient preferences and rapid advancements in interventional cardiology will propel the bioresorbable scaffolds market growth in the upcoming years. The incorporation of digital health solutions will also play a central role in the adoption of bioresorbable vascular scaffold in the near future.

Restraint - Biocompatibility concerns to dampen the market outlook

Concerns surrounding the biocompatibility of bioresorbable vascular scaffolds arise from the uncertainty of the body’s response to the scaffold material. This response, in turn, is likely to affect tissue integration and the overall healing process. On the other hand, the material used needs to have sufficient mechanical strength to support the body’s vascular structure while it degrades at a controlled rate. Addressing these interconnected challenges requires huge upfront investments in research & development activities, which can prove to be a major hurdle in the growth of the BVS market.

Opportunity - Supportive regulations and rising R&D investments to enhance the bioresorbable vascular scaffold market

The bioresorbable vascular scaffold industry is expected to make gains due to an increasingly favorable regulatory environment for innovative medical devices and procedures. Regulatory bodies are expediting the approval of new-age treatment options such as BVS, enabling quick market entry to health-tech companies specializing in cardiac products and services. Additionally, the market is set to benefit from significant investments being made in R&D activities in this field. For example, in May 2024, a California-based healthcare technology company called R3 Vascular, raised US$ 87 million to develop bioresorbable scaffolds to treat peripheral arterial disease. The BVS market is poised for speedy expansion as a result of these innovation opportunities.

Category-wise Analysis

Product Insights

Based on product, the bioresorbable vascular scaffold market has been divided into metal bioresorbable vascular scaffold and polymer bioresorbable vascular scaffold. The polymer BVS segmented is set to lead the product category with a share of 89.7% in 2025. Polymer-based scaffolds are gaining traction due to their superior biocompatibility and controlled degradation rates, which align with the body's healing process. Innovations in biodegradable polymers and scaffold architecture are enhancing performance metrics such as radial strength and flexibility, positioning polymer scaffolds as a key growth driver.

Application Insights

Based on application, the bioresorbable vascular scaffold market has been segmented into coronary artery and peripheral artery. The market share for coronary artery is anticipated to dominate the market during the forecast period with a positive CAGR through 2032. The emergence of CAD as a leading cause of death worldwide in recent years and the growing demand for minimally invasive surgeries with faster recovery periods are the two primary factors driving this segment. Moreover, advancements in bioresorbable vascular scaffolds have made them more efficient and safer, increasing their adoption among cardiac patients and healthcare professionals alike.

End-user Insights

By end-user, the segmentation includes hospitals, ambulatory care centers, cardiac centers, and others. Among these hospitals are expected to showcase a leading CAGR through 2032, holding a major share in the bioresorbable vascular scaffold market. Hospitals are the most preferred locations for cardiovascular treatments due to the availability of healthcare professionals and advanced medical infrastructure.

Regional Insights

North America Bioresorbable Vascular Scaffold Market Trends

North America dominates the bioresorbable vascular scaffold market and is expected to grow at a 7.70% CAGR through 2032. The region boasts a robust healthcare infrastructure, high spending ability, and strong healthcare expenditure, enabling swift adoption of next-generation medical technologies such as BVS. Additionally, rising incidence of CVD and CAD among the US population will further boost the regional market. Favorable regulations and heavy investments in healthcare R&D are also key factors driving the bioresorbable scaffolds market in North America.

East Asia Bioresorbable Vascular Scaffold Market Trends

East Asia Market is projected to secure a CAGR of 9.21% in the forecast period by 2032. The region’s increasing healthcare expenditure and advancements in medical technology drive demand for innovative cardiovascular treatments. Furthermore, growing awareness among healthcare professionals and patients about the benefits of bioresorbable scaffolds over traditional stents is accelerating the adoption.

Additionally, favorable government initiatives supporting the development of healthcare infrastructure and the rising incidence of cardiovascular diseases contribute to market growth. With expanding access to advanced healthcare facilities and a rise in an aging population prone to cardiac ailments, East Asia offers more opportunities for market expansion.

Competitive Landscape

The global bioresorbable vascular scaffold market is competitive. Growing R&D investments to develop, launch, and expand the product portfolio is a key strategy observed in the last couple of years. The leading industry players are expanding their manufacturing capabilities and simultaneously their presence in the global industry.

Key Industry Developments:

• In April 2024, Abbott’s Esprit™ BTK System received FDA approval for treating chronic limb-threatening ischemia (CLTI) below the knee. It delivers Everolimus, supports vessel healing, and fully dissolves over time.
• In February 2024, Biotronik launched Freesolve™ Resorbable Magnesium Scaffold (RMS) and secured CE approval. As a third-generation RMS, it enables magnesium resorption within 12 months, offering optimized support for vascular healing.
• In June 2023, Zeus introduced Absorv™ XSE oriented tubing, a next-gen solution for bioresorbable vascular scaffolds, providing a viable alternative to permanent metallic implants.

Companies Covered in Bioresorbable Vascular Scaffold Market

• Meril Life Sciences Pvt. Ltd.
• Zeus Company LLC
• Biotronik
• Abbott
• MicroPort Scientific Corporation
• Kyoto Medical
• Elixir Medical (MedImpact Healthcare Systems, Inc.)
• Cigna
• B. Braun Melsungen AG
• Boston Scientific Corporation
• REVA Medical